1. INTRODUCTION
1.1. MARKET OVERVIEW
1.2. MARKET DEFINITION
1.3. SCOPE OF THE STUDY
1.4. CURRENCY
1.5. ASSUMPTIONS
1.6. BASE AND FORECAST YEARS TIMELINE
2. RESEARCH METHODOLOGY
2.1. RESEARCH DESIGN
2.2. SECONDARY SOURCES
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. MARKET SEGMENTATION
4.2. MARKET DRIVERS
4.3. MARKET RESTRAINTS
4.4. MARKET OPPORTUNITIES
4.5. PORTER’S FIVE FORCE ANALYSIS
4.5.1. BARGAINING POWER OF SUPPLIERS
4.5.2. BARGAINING POWER OF BUYERS
4.5.3. THREAT OF NEW ENTRANTS
4.5.4. THREAT OF SUBSTITUTES
4.5.5. COMPETITIVE RIVALRY IN THE INDUSTRY
4.6. LIFE CYCLE ANALYSIS - REGIONAL SNAPSHOT
4.7. MARKET ATTRACTIVENESS
5. BIOPHARMACEUTICALS FERMENTATION SYSTEMS MARKET BY PRODUCT
5.1. UPSTREAM PRODUCTS
5.2. DOWNSTREAM PRODUCTS
6. BIOPHARMACEUTICALS FERMENTATION SYSTEMS MARKET BY APPLICATION
6.1. RECOMBINANT PROTEINS
6.2. MONOCLONAL ANTIBODIES
6.3. ANTIBIOTICS
6.4. PROBIOTICS
7. BIOPHARMACEUTICALS FERMENTATION SYSTEMS MARKET BY END USER
7.1. BIOPHARMACEUTICALS COMPANIES
7.2. CONTRACT MANUFACTURING COMPANIES
7.3. ACADEMIC RESEARCH INSTITUTIONS
7.4. FOOD INDUSTRY
8. BIOPHARMACEUTICALS FERMENTATION SYSTEMS MARKET BY GEOGRAPHY
8.1. NORTH AMERICA
8.1.1. USA
8.1.2. CANADA
8.1.3. MEXICO
8.2. SOUTH AMERICA
8.2.1. BRAZIL
8.2.2. ARGENTINA
8.2.3. OTHERS
8.3. EUROPE
8.3.1. GERMANY
8.3.2. FRANCE
8.3.3. UNITED KINGDOM
8.3.4. SPAIN
8.3.5. OTHERS
8.4. MIDDLE EAST AND AFRICA
8.4.1. SAUDI ARABIA
8.4.2. ISRAEL
8.4.3. OTHERS
8.5. ASIA PACIFIC
8.5.1. CHINA
8.5.2. JAPAN
8.5.3. SOUTH KOREA
8.5.4. INDIA
8.5.5. OTHERS
9. COMPETITIVE INTELLIGENCE
9.1. COMPANY BENCHMARKING AND ANALYSIS
9.2. RECENT INVESTMENT AND DEALS
9.3. STRATEGIES OF KEY PLAYERS
10. COMPANY PROFILES
10.1. GE HEALTHCARE
10.2. MERCK KGAA
10.3. THERMO FISHER SCIENTIFIC
10.4. SARTORIUS STEDIM BIOTECH
10.5. DANAHER CORPORATION
10.6. EPPENDORF AG
10.7. F. HOFFMAN-LA ROCHE LTD
10.8. NOVA BIOMEDICAL
10.9. LONZA
10.10. BECTON DICKINSON AND COMPANY
LIST OF FIGURES
LIST OF TABLES